🟡 Medium ImpactPharma
Aurobindo Pharma gets USFDA nod for Tofacitinib tablets
Aurobindo Pharma gets USFDA nod for Tofacitinib tablets — Shares rise on approval of generic drug for rheumatoid arthritis. The greenlight allows Aurobindo to market Tofacitinib in 60 mg strength, boosting its US portfolio. This expands its presence in the $XX million chronic inflammation market. Approval may contribute to future revenue growth.
📊 STOCKS: AUROPHARMA | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #USFDA
#USFDA#approval#AurobindoPharma
Stocks mentioned
⚠️ This brief is AI-generated from public news sources for informational purposes only. Not investment advice. Always consult a SEBI-registered advisor before trading.
Next article
markets rise ahead of rbi policy →Trade smarter on NSE
Live option chains, FII flows, PCR, AI analysis — for NIFTY, BANKNIFTY & 200+ F&O stocks.
Start for ₹1 →